Consider Jakafi®…
Webcast Event
Consider Jakafi® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD
Featured Speaker:
Jonathan Abbas, MD
Tennessee Oncology
Nashville, TN
Register here.
You may also register by contacting your Incyte Representative Carole Yates at (415) 518-3889 or cyates@incyte.com with the following information: name, title/ degree, state(s) and state license number(s), affiliation, address, phone and email.